IMPROVE THE STANDARD OF CARE IN THE USA
Prevent avoidable deaths!
Prevent avoidable deaths!
Testing for DPD/DPYD deficiency prior to the start of chemotherapy with 5-FU (Fluorouracil) or Capecitabine (Xeloda) can reduce suffering and save lives.
Testing for DPD/DPYD deficiency prior to the start of chemotherapy with 5-FU or Capecitabine (Xeloda) can reduce suffering and save lives.
Testing for DPD/DPYD deficiency is becoming the standard of care across Europe and in select institutions in the US: it is time for it to become THE standard of care across all of the US.
What you need to know:
Our Mission
To improve the standard of care in the United States for cancer patients undergoing fluoropyrimidine chemotherapy (5-FU and/or Capecitabine), through advocacy, education and research.